Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women's Health Inc. develops and commercializes noninvasive, AI-powered blood tests used in gynecologic disease diagnostics and disease management. Company news centers on OvaSuite, which includes OvaWatch and Ova1Plus, and on Ova1 and Overa as FDA-cleared components used to assess ovarian malignancy risk in women with adnexal masses.
Recurring updates also cover ENDOinform, a blood draw-based multi-omics test in development for endometriosis using protein and microRNA biomarkers with patient-specific data. Other company developments include financial results, ARPA-H program milestones, OTCQB trading status, equity and capital actions, and board or governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.